Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for rare genetic diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The grants, announced on April 11, 2025, include an aggregate of 96,800 options with an exercise price of $2.72 per share, matching the closing price on April 7, 2025.
The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters, contingent on continued employment.
Fulcrum Therapeutics (FULC), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di piccole molecole per malattie genetiche rare, ha concesso opzioni su azioni a due nuovi dipendenti nell'ambito del suo Piano di Incentivazione per Azioni per il 2022. Le concessioni, annunciate l'11 aprile 2025, includono un totale di 96.800 opzioni con un prezzo di esercizio di $2,72 per azione, corrispondente al prezzo di chiusura del 7 aprile 2025.
Le opzioni hanno un termine di dieci anni e seguono un piano di maturazione di quattro anni: il 25% matura al primo anniversario di assunzione, seguito dal 6,25% che matura trimestralmente nei successivi dodici trimestri, a condizione di continuare a essere impiegati.
Fulcrum Therapeutics (FULC), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de pequeñas moléculas para enfermedades genéticas raras, ha otorgado opciones sobre acciones a dos nuevos empleados bajo su Plan de Incentivos de Acciones por Inducción de 2022. Las concesiones, anunciadas el 11 de abril de 2025, incluyen un total de 96,800 opciones con un precio de ejercicio de $2.72 por acción, coincidiendo con el precio de cierre del 7 de abril de 2025.
Las opciones tienen un plazo de diez años y siguen un calendario de adquisición de cuatro años: el 25% se adquiere en el primer aniversario de empleo, seguido del 6.25% que se adquiere trimestralmente durante los siguientes doce trimestres, condicionado a la continuación del empleo.
Fulcrum Therapeutics (FULC), 희귀 유전 질환을 위한 소분자 개발에 초점을 맞춘 임상 단계의 생명공학 회사가 2022년 유도 주식 인센티브 계획에 따라 두 명의 신규 직원에게 주식 옵션을 부여했습니다. 2025년 4월 11일에 발표된 이 부여는 96,800개의 옵션을 포함하며, 행사 가격은 주당 $2.72로, 2025년 4월 7일의 종가와 일치합니다.
옵션은 10년의 기간을 가지며 4년의 베스팅 일정에 따릅니다: 첫 번째 고용 기념일에 25%가 베스트되고, 이후 12분기 동안 분기마다 6.25%가 베스트됩니다. 이는 계속 고용되는 것을 조건으로 합니다.
Fulcrum Therapeutics (FULC), une entreprise biopharmaceutique en phase clinique axée sur le développement de petites molécules pour les maladies génétiques rares, a accordé des options d'achat d'actions à deux nouveaux employés dans le cadre de son Plan d'Incitation à l'Action de 2022. Les attributions, annoncées le 11 avril 2025, comprennent un total de 96 800 options avec un prix d'exercice de 2,72 $ par action, correspondant au prix de clôture du 7 avril 2025.
Les options ont une durée de dix ans et suivent un calendrier d'acquisition de quatre ans : 25 % sont acquises lors du premier anniversaire de l'emploi, suivies de 6,25 % acquises trimestriellement au cours des douze trimestres suivants, sous réserve de la poursuite de l'emploi.
Fulcrum Therapeutics (FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung kleiner Moleküle für seltene genetische Erkrankungen konzentriert, hat zwei neuen Mitarbeitern im Rahmen seines Induktionsaktienoptionsplans 2022 Aktienoptionen gewährt. Die am 11. April 2025 bekannt gegebenen Zuteilungen umfassen insgesamt 96.800 Optionen mit einem Ausübungspreis von 2,72 $ pro Aktie, was dem Schlusskurs vom 7. April 2025 entspricht.
Die Optionen haben eine Laufzeit von zehn Jahren und folgen einem vierjährigen Vesting-Plan: 25% werden am ersten Jubiläum des Arbeitsverhältnisses fällig, gefolgt von 6,25%, die in den nächsten zwölf Quartalen vierteljährlich fällig werden, vorausgesetzt, das Arbeitsverhältnis besteht weiterhin.
- Employee retention strategy implemented through long-term stock options
- Alignment of employee interests with shareholders through equity compensation
- Potential future dilution of existing shareholders from 96,800 new stock options
CAMBRIDGE, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum granted the new employees an aggregate of 96,800 options to purchase shares of the company’s common stock at an exercise price of
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
What is the exercise price for FULC's newly granted stock options in April 2025?
How many stock options did Fulcrum Therapeutics (FULC) grant to new employees in April 2025?
What is the vesting schedule for FULC's April 2025 employee stock options?
How long is the term of FULC's April 2025 employee stock options?
